Faslodex-Arimidex Improves Survival in Post-menopausal Women with Advanced BC, Trial Shows

Faslodex-Arimidex Improves Survival in Post-menopausal Women with Advanced BC, Trial Shows
First-line treatment with Arimidex (anastrozole) plus Faslodex (fulvestrant) prolongs the lives of post-menopausal women with hormone receptor (HR)-positive advanced breast cancer, particularly those who have never taken tamoxifen, results of a clinical trial show. The study, “Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer,” was published in the New England Journal of Medicine. Faslodex, developed by AstraZeneca, is approved for HR-positive advanced breast cancer in women who have been through menopause, including those who have not received prior hormone therapy, also known as endocrine therapy (e.g. the anti-estrogen medication tamoxifen), and those whose cancer got worse after taking a hormonal treatment.
Subscribe or to access all post and page content.